Boiling the boil

Clinical Infectious Diseases

Volumn 40, Issue 8, 2005, Pages 1156-1158

  Wortmann, Glenn ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; DICLOXACILLIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; STIBOGLUCONATE SODIUM;

CELLULITIS; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; HUMAN; HYPERTHERMIC THERAPY; INCIDENCE; NOTE; PRIORITY JOURNAL; RADIOFREQUENCY; SIDE EFFECT; SKIN LEISHMANIASIS; TREATMENT OUTCOME; TREATMENT PLANNING; VISCERAL LEISHMANIASIS;

ANTIPROTOZOAL AGENTS; HUMANS; HYPERTHERMIA, INDUCED; LEISHMANIASIS, CUTANEOUS;

EID: 16844378673     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/428738     Document Type: Note

References (14)

1. McHugh C, Melby P, LaFon S. Leishmaniasis in Texas: Epidemiology and clinical aspects of human cases. Am J Trop Med Hyg 1996; 55:547-55.
2. Gaskin A, Schantz P, Jackson J, et al. Visceral leishmaniasis in a New York foxhound kennel. J Vet Intern Med 2002; 16:34-44.
3. Weina P, Neafie R, Wortmann G, Polhemus M, Aronson N. Old World Leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis 2004; 39:1674-80.
4. Centers for Disease Control and Prevention. Two cases of visceral leishmaniasis in U.S. military personnel - Afghanistan, 2002-2004. MMWR Morb Mortal Wkly Rep 2004; 53:265-8.
5. Thakur CP, Dedet JP, Narain S, Pratlong F. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India. Trans R Soc Trop Med Hyg 2001; 5:187-9.
6. Myerhoff A. US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28:42-8.
7. Hale V, Herskowtiz A, Battacharya S, et al. Paromomycin as a new cure for visceral leishmaniasis: initial results of a phase III multicenter, randomized, controlled, clinical trial to assess safety and efficacy [abstract 48]. In: Program and abstracts of the 53rd Annual Meeting of the American Society of Tropical Medicine and Hygiene (Miami Beach). Northbrook, IL: American Society of Tropical Medicine and Hygiene, 2004:15.
8. Sundar S, Jha T, Thakur C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
9. Alrajhi A, Ibrahim E, De Vol E, Khairat M, Faris R, Maguire J. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-5.
10. Herwaldt B, Arana B, Navin T. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:518-27.
11. Reithinger R, Mohsen M, Wahid M, et al. The efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 2005; 40:1148-55 (in this issue).
12. Navin T, Arana B, Arana F, De Merida A, Castillo A, Pozuelos J. Placebo-controlled clinical trial of meglumine antimonite (Glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990; 42:43-50.
13. Velasco-Castrejon O, Wallon B, Rivas-Sanchez B, et al. Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. Am J Trop Med Hyg 1997; 57:309-12.
14. Aronson N, Wortmann G, Byrne W, et al. A randomized trial of sodium stibogluconate versus heat therapy in cutaneous Leishmania major [abstract P428]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004:452.